Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (61-70 of 1,058) with videos related to

Pageof 106
Sort By:
Blood|January 8, 2014
How will B-cell-receptor-targeted therapies change future CLL therapy?Jeffrey A Jones, John C Byrd
Hospitals|March 16, 1971
Convenience versus conventional operationR C Byrd, J T Morrow
Wisconsin Medical Journal|November 1, 1993
Smoking cessation among pregnant women in an urban settingJ C Byrd, C D Meade
Journal of the Medical Association of Georgia|April 1, 1997
Assisted living: meeting the needs of an aging GeorgiaW C Byrd, S B Byrd
JAMA|April 3, 1981
The click-murmur syndrome. A clinical problem in diagnosis and treatmentM D Cheitlin, R C Byrd
The Journal of Biological Chemistry|April 15, 2000
Mechanisms for high affinity mannose 6-phosphate ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptorJ C Byrd, R G MacDonald
Seminars in Oncology|August 19, 2000
What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?J C Byrd, K R Rai
Cancer Metastasis Reviews|March 6, 2004
Mucins and mucin binding proteins in colorectal cancerJames C Byrd, Robert S Bresalier
Advances in Pharmacology (San Diego, Calif.)|October 7, 2004
Monoclonal antibody therapy in lymphoid leukemiasThomas S Lin, John C Byrd
Gastroenterology|February 1, 1992
Efficacy of prophylactic sclerotherapy for prevention of a first variceal hemorrhageJ Van Ruiswyk, J C Byrd
Pageof 106

Showing results (61-70 of 1,058) with videos related to

Sort By:
Pageof 106
Blood|January 8, 2014
How will B-cell-receptor-targeted therapies change future CLL therapy?Jeffrey A Jones, John C Byrd
Hospitals|March 16, 1971
Convenience versus conventional operationR C Byrd, J T Morrow
Wisconsin Medical Journal|November 1, 1993
Smoking cessation among pregnant women in an urban settingJ C Byrd, C D Meade
Journal of the Medical Association of Georgia|April 1, 1997
Assisted living: meeting the needs of an aging GeorgiaW C Byrd, S B Byrd
JAMA|April 3, 1981
The click-murmur syndrome. A clinical problem in diagnosis and treatmentM D Cheitlin, R C Byrd
The Journal of Biological Chemistry|April 15, 2000
Mechanisms for high affinity mannose 6-phosphate ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptorJ C Byrd, R G MacDonald
Seminars in Oncology|August 19, 2000
What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?J C Byrd, K R Rai
Cancer Metastasis Reviews|March 6, 2004
Mucins and mucin binding proteins in colorectal cancerJames C Byrd, Robert S Bresalier
Advances in Pharmacology (San Diego, Calif.)|October 7, 2004
Monoclonal antibody therapy in lymphoid leukemiasThomas S Lin, John C Byrd
Gastroenterology|February 1, 1992
Efficacy of prophylactic sclerotherapy for prevention of a first variceal hemorrhageJ Van Ruiswyk, J C Byrd
Pageof 106